Retatrutide is an investigational agonist of GIP, GLP-1, and glucagon receptors being studied in obesity and type 2 diabetes.
Also known as 3(r) · 3g rt · 3g-rt · amp-3p · cp rt · cp-rt
Historical market context
Historical market low and median per mg across recorded offers. These market summaries are separate from our exact-product comparisons.
History updated Sep 21, 2026. Vendor coverage, package sizes, product forms and promotions can vary over time. Use exact-product comparisons for current listed prices; historical market prices do not establish vendor trust.
| Date | Low /mg | Median /mg | Vendors | Offers |
|---|---|---|---|---|
| $1.20 | $6.24 | 13 | 66 | |
| $1.20 | $6.24 | 13 | 66 | |
| $1.20 | $6.24 | 13 | 66 | |
| $1.20 | $6.24 | 13 | 66 | |
| $1.20 | $6.24 | 13 | 66 | |
| $1.20 | $6.58 | 13 | 66 | |
| $1.20 | $6.97 | 16 | 80 | |
| $1.20 | $6.97 | 16 | 80 | |
| $1.20 | $6.97 | 16 | 80 | |
| $1.20 | $6.97 | 16 | 80 | |
| $1.20 | $6.97 | 16 | 80 | |
| $1.20 | $7.82 | 16 | 89 | |
| $1.20 | $7.82 | 16 | 89 | |
| $1.20 | $7.81 | 16 | 90 | |
| $1.20 | $7.81 | 16 | 90 | |
| $1.20 | $7.81 | 16 | 90 | |
| $1.20 | $7.59 | 15 | 88 | |
| $1.20 | $7.59 | 15 | 88 | |
| $1.20 | $7.59 | 15 | 88 | |
| $1.20 | $7.20 | 16 | 93 | |
| $1.20 | $7.20 | 16 | 93 | |
| $1.20 | $7.11 | 16 | 92 | |
| $1.20 | $7.20 | 16 | 93 | |
| $1.20 | $6.67 | 14 | 80 | |
| $1.20 | $6.67 | 14 | 80 | |
| $1.20 | $6.67 | 14 | 80 | |
| $1.20 | $6.67 | 14 | 80 | |
| $1.20 | $6.67 | 14 | 80 | |
| $1.20 | $6.67 | 14 | 80 | |
| $1.20 | $6.67 | 14 | 79 | |
| $1.20 | $6.67 | 15 | 81 | |
| $1.20 | $6.63 | 15 | 78 | |
| $1.20 | $6.63 | 15 | 78 | |
| $1.20 | $6.67 | 15 | 81 | |
| $1.20 | $6.55 | 13 | 76 | |
| $1.20 | $6.33 | 14 | 89 | |
| $1.20 | $6.50 | 14 | 91 | |
| $1.20 | $6.67 | 16 | 94 | |
| $1.20 | $6.45 | 16 | 96 | |
| $1.20 | $6.50 | 16 | 97 | |
| $1.20 | $6.58 | 16 | 96 | |
| $1.20 | $6.80 | 17 | 106 | |
| $1.20 | $6.67 | 17 | 107 | |
| $1.20 | $6.67 | 17 | 107 | |
| $1.20 | $6.67 | 17 | 107 | |
| $1.20 | $6.67 | 18 | 105 | |
| $1.20 | $6.67 | 18 | 105 | |
| $1.20 | $7.20 | 17 | 87 | |
| $1.20 | $7.20 | 17 | 87 | |
| $1.20 | $7.02 | 16 | 85 | |
| $1.20 | $6.67 | 15 | 82 | |
| $1.20 | $6.67 | 14 | 81 | |
| $1.20 | $6.67 | 14 | 83 | |
| $1.20 | $6.67 | 14 | 83 | |
| $1.20 | $6.67 | 14 | 83 | |
| $1.20 | $6.67 | 14 | 83 | |
| $1.20 | $7.09 | 13 | 78 | |
| $1.20 | $6.67 | 12 | 71 | |
| $1.20 | $6.67 | 11 | 69 | |
| $1.20 | $6.67 | 11 | 69 | |
| $1.20 | $6.47 | 11 | 68 | |
| $1.20 | $6.47 | 11 | 70 | |
| $1.20 | $6.47 | 11 | 70 | |
| $1.20 | $6.47 | 11 | 70 | |
| $1.20 | $5.70 | 10 | 60 | |
| $1.20 | $4.80 | 8 | 53 | |
| $1.20 | $4.70 | 8 | 52 | |
| $1.20 | $4.86 | 9 | 57 | |
| $1.20 | $4.96 | 9 | 58 | |
| $1.20 | $4.96 | 9 | 58 | |
| $1.20 | $4.63 | 9 | 58 | |
| $1.20 | $4.42 | 9 | 58 | |
| $1.20 | $4.45 | 9 | 57 | |
| $1.20 | $4.51 | 9 | 56 | |
| $1.20 | $4.51 | 9 | 56 | |
| $1.20 | $4.45 | 9 | 57 | |
| $1.20 | $4.45 | 9 | 57 | |
| $1.20 | $4.51 | 9 | 56 | |
| $1.20 | $4.51 | 9 | 56 | |
| $1.20 | $4.45 | 9 | 55 | |
| $1.20 | $4.42 | 9 | 53 | |
| $1.20 | $4.42 | 9 | 53 | |
| $1.20 | $4.42 | 9 | 53 | |
| $1.20 | $4.80 | 10 | 63 | |
| $1.20 | $4.80 | 10 | 63 | |
| $1.20 | $4.80 | 10 | 62 | |
| $1.20 | $4.80 | 10 | 62 | |
| $1.20 | $4.81 | 8 | 47 | |
| $0.14 | $7.71 | 5 | 18 | |
| $0.14 | $6.81 | 7 | 38 | |
| $0.14 | $6.56 | 6 | 28 | |
| $2.50 | $6.95 | 7 | 39 | |
| $2.77 | $6.67 | 6 | 29 | |
| $2.50 | $8.00 | 6 | 29 | |
| $2.50 | $6.99 | 5 | 30 | |
| $2.50 | $6.99 | 5 | 30 | |
| $2.50 | $7.02 | 5 | 31 | |
| $2.50 | $7.02 | 5 | 31 | |
| $2.50 | $7.07 | 4 | 26 | |
| $2.50 | $6.00 | 3 | 21 | |
| $2.50 | $6.00 | 3 | 21 | |
| $2.50 | $6.00 | 3 | 21 | |
| $2.50 | $6.00 | 3 | 21 | |
| $2.50 | $6.00 | 3 | 21 | |
| $1.20 | $3.90 | 4 | 37 | |
| $1.20 | $3.86 | 3 | 36 | |
| $1.20 | $3.34 | 2 | 26 | |
| $1.20 | $3.38 | 3 | 27 |
Research shortlist · Sep 12, 2026
These research selections use the same basis: 10 mg vial. The selections remain from Sep 12, 2026; each price below comes from its dated market observation.
10 mg vial
10 mg vial
10 mg vial
What it is
ClinicalTrials.gov and PubMed index retatrutide under the development code LY3437943. The compound remains a development-stage therapy in this retained source set; online research products are not the clinical-trial supply.
This label describes the available research record, not whether the compound is safe or effective for an individual.
Research context
The bounded search found phase 2 and phase 3 human research involving weight and glycemic outcomes. Trial results apply to defined formulations, populations, and monitoring, and do not establish the identity or safety of vendor-sold material.
Search indexed research for this compound ↗Market context
Retatrutide is commonly sold or discussed for appetite, weight management, glucose control, and metabolic research. That describes market demand, not proof that the compound is safe or effective.
Market demand and online discussion do not establish product quality, safety, or effectiveness.Same format. Same amount.
16 of 17 formats had a qualifying research shortlist on Sep 12, 2026. Vendor counts below reflect the available price observations.
Vendor directory
Grades describe the vendor record overall. They are not a test result for every product.
| Vendor | Grade | Compared offers | In stock when checked | Lowest effective package | Profile |
|---|---|---|---|---|---|
| Amino ScienceVendor grade | Grade A- | 3 | 3 | $41.50Automatic buy x get y free · listed $82.9910 mg vial · compare →Observed Sep 21, 2026 | View → |
| EZ PeptidesVendor grade | Grade A- | 11 | 11 | $33.30Automatic buy x get y free · listed $376 mg vial · compare →Observed Sep 21, 2026 | View → |
| Nura PeptideVendor grade | Grade A- | Not available | Not available | Not availableNo market observation | View → |
| Peptide PlugsVendor grade | Grade A- | Not available | Not available | Not availableNo market observation | View → |
| Polaris PeptidesVendor grade | Grade A- | 4 | 4 | $505 mg vial · compare →Observed Sep 21, 2026 | View → |
| Evolve PeptidesVendor grade | Grade A- | 7 | 7 | $89.905 mg vial · compare →Observed Sep 21, 2026 | View → |
| GenPeptideVendor grade | Grade A- | Not available | Not available | Not availableNo market observation | View → |
| Orbitrex PeptidesVendor grade | Grade A- | 2 | 2 | $79.9910 mg vial · compare →Observed Sep 21, 2026 | View → |
| Puratek PeptidesVendor grade | Grade A- | Not available | Not available | Not availableNo market observation | View → |
| Southern AminosVendor grade | Grade A- | Not available | Not available | Not availableNo market observation | View → |
| Bulk Peptide SupplyVendor grade | Grade B+ | Not available | Not available | Not availableNo market observation | View → |
| Ameano PeptidesVendor grade | Grade B+ | 6 | 6 | $396 mg vial · compare →Observed Sep 21, 2026 | View → |
| Glacier AminosVendor grade | Grade B+ | Not available | Not available | Not availableNo market observation | View → |
| Peptide PartnersVendor grade | Grade B+ | Not available | Not available | Not availableNo market observation | View → |
| Alpha Pro PeptidesVendor grade | Grade B+ | 3 | 3 | $37.50Automatic buy x get y free · listed $74.9910 mg vial · compare →Observed Sep 21, 2026 | View → |
| Peptide CraftersVendor grade | Grade B+ | 4 | 4 | $8010 mg vial · compare →Observed Sep 21, 2026 | View → |
| Prime Lab PeptidesVendor grade | Grade B+ | Not available | Not available | Not availableNo market observation | View → |
| MedVinci ResearchVendor grade | Grade B+ | Not available | Not available | Not availableNo market observation | View → |
| Oasis PeptidesVendor grade | Grade B+ | Not available | Not available | Not availableNo market observation | View → |
| Oros ResearchVendor grade | Grade B+ | Not available | Not available | Not availableNo market observation | View → |
| PepvidaVendor grade | Grade B+ | Not available | Not available | Not availableNo market observation | View → |
| Silverstone LabsVendor grade | Grade B+ | 3 | 3 | $5910 mg vial · compare →Observed Sep 21, 2026 | View → |
| Licensed PeptidesVendor grade | Grade B+ | 4 | 0 | $359.955 mg vial · pack of 10 · compare →Observed Sep 21, 2026Out of stock when observed | View → |
| SaiyanMedVendor grade | Grade B+ | Not available | Not available | Not availableNo market observation | View → |
| Coffee and PeppersVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
| Ion PeptidesVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
| Paramount PeptidesVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
| NuLife PeptidesVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
| Premier Bio LabsVendor grade | Grade A- | 9 | 8 | $9.45Automatic quantity percent off · listed $155 mg vial · compare →Observed Sep 21, 2026 | View → |
| Amino AmigosVendor grade | Grade B+ | Not available | Not available | Not availableNo market observation | View → |
| Nationwide PeptidesVendor grade | Grade B+ | Not available | Not available | Not availableNo market observation | View → |
| VAYNVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
| Prime PeptidesVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
| NextGen PeptidesVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
| Blank PeptidesVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
| Royal PeptidesVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
| Mile High CompoundsVendor grade | Grade B | Not available | Not available | Not availableNo market observation | View → |
| NextechLabsVendor grade | Grade C | Not available | Not available | Not availableNo market observation | View → |
| Oath ResearchVendor grade | Grade C | Not available | Not available | Not availableNo market observation | View → |
| AIO PeptidesNot enough information to grade | Not enough information to grade | 3 | 3 | $53.76Automatic percent off · listed $67.2010 mg vial · compare →Observed Sep 21, 2026 | View → |
| American Peptide ResearchNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
| Longevity PeptidesNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
| Next ChemsNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
| Northline LabsNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
| Nova Life PeptidesNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
| Nuscience PeptidesNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
| OupeptideNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
| Peptides 4 ResearchNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
| Planet PeptideNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
| Pura PeptidesNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
| Skye PeptidesNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
| TydesNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
Sources and review
Last editorial review: Aug 30, 2026. Sources support the compound guide only and do not affect vendor grades.